@FierceMedDev: Lombard Medical in the U.K. detailed plans for a proposed $80M IPO driven by its aortic repair device. S-1 form | Follow @FierceMedDev
@MarkHFierce: Exosome Diagnostics raised $27M to bring its prostate cancer urine test to market. More | Follow @MarkHFierce
@MichaelGFierce: Nanoparticles breach blood-brain barrier as possible Alzheimer's treatment. Item from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Industry report shows bleak 2013 for med tech industry. Story | Follow @EmilyWFierce
@GalenMoore: Spanish researchers find a protein adults need for brain plasticity could delay the effects of Alzheimer's disease. Abstract | Follow @GalenMoore
> Medical device manufacturers face a looming deadline to start complying with the FDA's Unique Device Identification System, but some of the practical implications remain unresolved. Story
> Utah's Domain Surgical has raised $11.6 million to help back the advance of its device that enables soft tissue cutting and coagulation. Story
> The chairman of AngioDynamics ($ANGO) has retired, and the medical device manufacturer said his departure "is not the result of any disagreement." Story
> MedShape gained 510(k) clearance for its Morphix SP Suture Anchor. Story
> Minnesota's Sterilucent gained a CE mark for its hydrogen peroxide sterilizer and sterilant, a product recently exhibited at a major trade show in Germany, Story
Biotech News
@FierceBiotech: Kythera buys back Bayer's stake in PhIII chin-fat therapy in $84M deal. News | Follow @FierceBiotech
@JohnCFierce: Commentary--The dying child vs. the biotech: Everybody loses. Editor's Corner | Follow @JohnCFierce
@DamianFierce: Yesteryear's megamergers are, in part, driving Big Pharma's external R&D push, says John LaMattina. Forbes piece | Follow @DamianFierce
@EmilyMFierce: Scientists from Notre Dame ID new class of antibiotics to combat MRSA. Story | Follow @EmilyMFierce
> Lumena banks $45M and hits the gas on two liver treatments. More
> Novartis's new Basel campus reflects Vasella's (now out-of-fashion) style. Article
Pharma News
@FiercePharma: Yesterday's top-read news: Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year. Story | Follow @FiercePharma
@TracyStaton: Every Dog Has Its Data: The quantified self for pets, via The New York Times. Article (sub. req.) | Follow @TracyStaton
@EricPFierce: Pfizer's Effexor XR one of a host of recalls lately that include products from Mylan, Baxter and Gilead. More | Follow @EricPFierce
@CarlyHFierce: As promised: BTG recoils at rattlesnake roundup 'gassing.' Item | Follow @CarlyHFierce
> Bayer's Nexavar falls short in new liver cancer trial. Story
> Pharma wins battle against proposed Medicare reimbursement changes. More
Biotech Research News
> University of Notre Dame team IDs new class of antibiotics. Article
> Stem cell therapy improves Parkinson's symptoms in monkeys. Story
> NIH faces flat funds in president's 2015 budget proposal. News
> Seattle BioMed receives $10M NIAID grant to lead AIDS vaccine effort. News
> Antipsychotic drugs may have another use: Treating deadly brain tumors. Story
> OHSU opens new stem cell research center. Brief
Pharma Manufacturing News
> BMS joins Merck with plans to whack plants in Ireland. News
> Global rise in pain drug use puts the hurt on Tasmania's poppy production. Story
> Source: Ranbaxy shops for Nexium API to salvage lucrative launch. Article
> Ranbaxy recalls generic Lipitor after druggist finds 20-mg dose in 10-mg bottle. News
> Pfizer recalls bottles of antidepressant that might have a heart drug mixed in. Story
> Pfizer is expanding its plant in Indonesia--again. Brief